Product
Cipaglucosidase Alfa
Aliases
ATB200
2 clinical trials
1 indication
Indication
Pompe DiseaseClinical trial
A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/PlaceboStatus: Completed, Estimated PCD: 2020-12-15
Clinical trial
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years With Late-onset Pompe DiseaseStatus: Recruiting, Estimated PCD: 2026-06-01